Vanguard Asset Management
AXSM icon

Vanguard Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Vanguard Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45M Buy
38,610
+4,730
+14% +$1.03M 0.01% 743
2026
Q1 		$5.73M Buy
+33,880
New +$5.85M ﹤0.01% 873

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Asset Management's AXSM Position: Q2 2026 in Review

Vanguard Asset Management increased its Axsome Therapeutics (AXSM) stake by 14% in Q2 2026, buying an estimated $1.03M and bringing the position to 38,610 shares worth $9.45M. The position accounts for 0.01% of the portfolio, ranked #743.

Vanguard Asset Management first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 497 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Vanguard Asset Management held 38,610 shares of Axsome Therapeutics worth $9.45M as of Q2 2026.
  • Vanguard Asset Management bought 4,730 Axsome Therapeutics shares in Q2 2026, an estimated $1.03M.
  • Axsome Therapeutics made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #743 holding.
  • Vanguard Asset Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 497 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.